Univariate analysis of clinical outcome for the study population (n = 292) according to bcl-2 expression and treatment
. | CHOP . | . | . | R-CHOP . | . | . | ||
|---|---|---|---|---|---|---|---|---|
. | Bcl-2+ . | bcl-2- . | P . | Bcl-2+ . | bcl-2- . | P . | ||
| Response (%) | ||||||||
| CR/CRu | 56 (60) | 33 (73) | .1 | 79 (78) | 41 (76) | .8 | ||
| Non-CR | 36 (40) | 12 (27) | 22 (22) | 13 (24) | ||||
| 2-y survival, % | ||||||||
| OS | 48 ± 11 | 67 ± 14 | .05 | 67 ± 9 | 72 ± 12 | .7 | ||
| EFS | 32 ± 9 | 40 ± 14 | .14 | 58 ± 9 | 60 ± 12 | .8 | ||
. | CHOP . | . | . | R-CHOP . | . | . | ||
|---|---|---|---|---|---|---|---|---|
. | Bcl-2+ . | bcl-2- . | P . | Bcl-2+ . | bcl-2- . | P . | ||
| Response (%) | ||||||||
| CR/CRu | 56 (60) | 33 (73) | .1 | 79 (78) | 41 (76) | .8 | ||
| Non-CR | 36 (40) | 12 (27) | 22 (22) | 13 (24) | ||||
| 2-y survival, % | ||||||||
| OS | 48 ± 11 | 67 ± 14 | .05 | 67 ± 9 | 72 ± 12 | .7 | ||
| EFS | 32 ± 9 | 40 ± 14 | .14 | 58 ± 9 | 60 ± 12 | .8 | ||